Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel
NASDAQ:IMMP

Prima BioMed H2 2026 Earnings Report

Prima BioMed logo
$0.39 +0.01 (+2.40%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$0.39 0.00 (-0.08%)
As of 06:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Prima BioMed EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

Prima BioMed Revenue Results

Actual Revenue
N/A
Expected Revenue
$11.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prima BioMed Announcement Details

Quarter
H2 2026
Date
9/2/2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 26, 2026
Conference Call Time
6:00PM ET

Conference Call Resources

Prima BioMed Earnings Headlines

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survival-data-from-insight-003-and-update-from-tacti-004.html
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
July 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immutep-limited-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--immp-302818606.html
The oil crisis is spreading faster than you think
Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG capacity remains offline after missile strikes. Goldman Sachs named the UK the developed economy most exposed to a jet-fuel crunch, citing critically low reserves and a gutted refining base. Dow Chemical has already doubled polyethylene prices overnight. Garrett Goggin, CFA, CMT, points to four gold miners positioned for what comes next.tc pixel
August 12 at 1:00 AM  |  Golden Portfolio (Ad)
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321395/0/en/immp-investors-have-opportunity-to-lead-immutep-limited-securities-fraud-lawsuit-with-the-schall-law-firm.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
July 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immutep-limited-of-class-action-lawsuit-and-upcoming-deadlines--immp-302815519.html
IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320706/0/en/immutep-limited-investors-with-losses-have-until-july-6-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html
See More Prima BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prima BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prima BioMed and other key companies, straight to your email.

About Prima BioMed

Prima BioMed (NASDAQ:IMMP), trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers.

Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation.

Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.

View Prima BioMed Profile
Earnings Tools